HC Wainwright Issues Negative Forecast for Invivyd Earnings

Invivyd, Inc. (NASDAQ:IVVD) – Research analysts at HC Wainwright reduced their Q2 2026 EPS estimates for Invivyd in a research note issued to investors on Tuesday, May 19th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.15) per share for the quarter, down from their previous estimate of ($0.09). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Invivyd’s Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.48) EPS and FY2027 earnings at ($0.28) EPS.

Invivyd (NASDAQ:IVVD) last announced its earnings results on Thursday, May 14th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.05). The firm had revenue of $13.74 million during the quarter, compared to analysts’ expectations of $18.04 million. Invivyd had a negative net margin of 138.90% and a negative return on equity of 53.48%.

Other research analysts also recently issued reports about the stock. BTIG Research restated a “buy” rating and issued a $10.00 target price on shares of Invivyd in a research note on Monday. Wall Street Zen downgraded shares of Invivyd from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Invivyd in a research note on Wednesday, April 29th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $8.00.

Invivyd Trading Up 4.8%

Shares of IVVD stock opened at $1.09 on Thursday. The company has a market capitalization of $321.12 million, a PE ratio of -3.52 and a beta of 0.71. The firm has a fifty day simple moving average of $1.48 and a 200-day simple moving average of $1.88. Invivyd has a twelve month low of $0.48 and a twelve month high of $3.07.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in IVVD. Perceptive Advisors LLC bought a new position in Invivyd during the 4th quarter valued at $53,809,000. BVF Inc. IL bought a new position in Invivyd during the 4th quarter valued at $48,227,000. RA Capital Management L.P. bought a new position in Invivyd during the 3rd quarter valued at $18,831,000. ADAR1 Capital Management LLC bought a new position in Invivyd during the 3rd quarter valued at $8,108,000. Finally, Janus Henderson Group PLC boosted its stake in Invivyd by 28.2% during the 4th quarter. Janus Henderson Group PLC now owns 32,543,142 shares of the company’s stock valued at $80,870,000 after acquiring an additional 7,160,065 shares during the last quarter. 70.36% of the stock is currently owned by institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.